Advanced Biomanufacturing
Gene Bio Medical is a Canadian biotechnology company advancing the future of biomanufacturing through the integration of artificial intelligence, automation, advanced diagnostics, and scalable production technologies.
Our biomanufacturing platform supports the development and commercialization of next-generation diagnostic products, including molecular diagnostics, rapid point-of-care tests, microfluidic systems, immunoassays, and precision healthcare solutions. By combining scientific innovation with advanced engineering, we enable the efficient, cost-effective, and scalable production of high-quality healthcare technologies for global markets.
Intelligent Manufacturing for Healthcare Innovation
We leverage advanced manufacturing technologies, automation systems, digital quality control, and data-driven process optimization to enhance productivity, consistency, and product performance throughout the manufacturing lifecycle. Our integrated approach accelerates the transition from research and development to large-scale commercialization while maintaining the highest quality standards.
Gene Bio Medical develops and manufactures advanced lateral flow immunoassays (LFAs), one of the most widely used rapid diagnostic technologies in healthcare. These user-friendly diagnostic platforms enable the rapid detection of pathogens, biomarkers, infectious diseases, and other health conditions across human health, animal health, food safety, and environmental monitoring applications.
Our rapid diagnostic solutions are designed to deliver fast, accurate, and reliable results while supporting decentralized testing and improved access to healthcare worldwide.
| Lateral flow test (LFT) | Express test |
| Lateral flow device (LFD) | Pen-side test |
| Lateral flow assay (LFA) | Quick test |
| Lateral flow immunoassay (LFIA) | Rapid test |
| Lateral flow immunochromatographic assays | Test strip |
Lateral flow tests (LFDs) operate based on immunoassay technology, employing components such as nitrocellulose membrane, colored nanoparticles or labels, and antibodies to generate results.
When a sample is applied to the test device, it flows through the conjugate pad and onto the nitrocellulose membrane. Finally, it reaches the absorbent pad, completing the flow along the test device.
Regardless of the label types, they all perform the same function to create a three-way bond with antibodies and targets in order to make the control and test lines visible.
Diagnostic technology is rapidly advancing, particularly in antibody identification, in automated clinical chemistry laboratories. With a wide dynamic range, high sensitivity and specificity, quantitative results, automation, reduced turnaround time, and the ability to conduct multiple antibody tests on large antigenic panels, this technology is highly advanced in clinical laboratories. It significantly impacts workflow and the organization of autoimmunology labs.
Anticipated advancements in the coming years include the introduction of new analytical platforms like flow-injection chemiluminescent immunoassay, two-dimensional resolution for chemiluminescence multiplex immunoassay, and magnetic nanoparticles chemiluminescence immunoassay. These developments are expected to enhance the clinical efficacy of antibody tests.
Chemiluminescent analytical methods offer key advantages, including a wide dynamic range, high signal intensity, absence of interfering emissions (ensuring high specificity), rapid signal acquisition, stable reagents and conjugates, low reagent consumption, random access capability, reduced incubation time, and compatibility with immunology assay protocols. However, it is important to acknowledge that there are also some unforeseen limitations to be considered.
Gene Bio Medical’s microfluidic platform miniaturizes complex laboratory processes onto compact and highly efficient diagnostic chips. By combining microfluidics with advanced detection systems, including chemiluminescence, fluorescence, and AI-assisted analysis, we enable rapid, automated, and highly sensitive testing solutions.
These technologies support high-throughput screening, multiplex testing, reduced reagent consumption, and improved analytical performance, creating new opportunities for point-of-care diagnostics, precision medicine, and future healthcare applications.
Building the Future of Healthcare
Through continuous innovation, strategic partnerships, and investments in advanced biomanufacturing, Gene Bio Medical is building a globally competitive platform for AI-enabled diagnostics, precision health, and next-generation healthcare technologies. Our vision is to strengthen healthcare resilience, expand Canadian biomanufacturing capacity, and improve health outcomes for communities around the world.